NYSEARCA:LABD Direxion Daily S&P Biotech Bear 3x Shares (LABD) Price, Holdings, & News → This Weight Loss Company Can't Make Enough Product (From Behind the Markets) (Ad) Free LABD Stock Alerts $7.99 +0.32 (+4.17%) (As of 06/17/2024 ET) Add Compare Share Share Today's Range$7.75▼$8.1150-Day Range$7.10▼$11.0352-Week Range$5.72▼$29.92Volume8.33 million shsAverage Volume15.00 million shsMarket Capitalization$90.45 millionAssets Under Management$121.77 millionDividend Yield1.13%Net Expense Ratio1.10% Stock AnalysisStock AnalysisChartHoldingsOwnershipStock AnalysisChartHoldingsOwnership Get Direxion Daily S&P Biotech Bear 3x Shares alerts: Email Address About Direxion Daily S&P Biotech Bear 3x SharesThe Direxion Daily S&P Biotech Bear 3X Shares (LABD) is an exchange-traded fund that is based on the S&P Biotechnology Select Industry index. The fund provides daily 3 times inverse exposure to the S&P Biotechnology Select Industry Index. LABD was launched on May 28, 2015 and is managed by Direxion.Read More LABD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LABD ETF News HeadlinesMarch 21, 2024 | msn.comDirexion Daily S&P Biotech Bear 3X Shares declares quarterly distribution of $0.0664March 2, 2024 | msn.comSOXS, ARKB and LABD among weekly ETF moversJuly 21, 2023 | msn.comLABD: 3X Leveraged Inverse Fund In Biotechnology Sector Is Best AvoidedJune 22, 2023 | msn.comDirexion Daily S&P Biotech Bear 3X Shares declares quarterly distribution of $0.0998June 22, 2023 | msn.com5 Factors Why Inverse ETFs May Rule in 2H23March 1, 2023 | msn.com5 Best Inverse-Leveraged ETFs of FebruaryFebruary 24, 2023 | finance.yahoo.comThis Year's Most Shorted ETFsFebruary 15, 2023 | finance.yahoo.com5 Least-Hurt Biotech ETFs of the Last WeekSee More Headlines Receive LABD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Direxion Daily S&P Biotech Bear 3x Shares and its competitors with MarketBeat's FREE daily newsletter. Email Address Fund Details IssuerDirexion Fund NameDirexion Daily S&P Biotech Bear 3x Shares Tax ClassificationRegulated Investment Company Stock ExchangeNYSEARCACurrent SymbolNYSEARCA:LABD Inception Date5/28/2015 Fund ManagerPaul Brigandi, Tony Ng WebN/A PhoneN/AFund Focus Asset ClassEquity BenchmarkS&P Biotechnology Select Industry Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings13 Fund Statistics Assets Under Management$121.77 million Average Daily Volume$13.56 million Discount/Premium-0.03% Leveraged-3.00 Administrator, Advisor and Custodian AdministratorU.S. Bancorp Fund Services, LLC AdvisorRafferty Asset Management, LLC CustodianThe Bank of New York Mellon Corporation DistributorForeside Fund Services, LLC Transfer AgentThe Bank of New York Mellon Corporation TrusteeN/A Lead Market MakerVirtu Financial Options OptionableOptionable Options Volume3,122 Put Options653 Call Options2,469 Short Interest2,300,000 shs Miscellaneous Outstanding Shares11,320,000Beta-3.24 Creation Unit50,000 Creation Fee$250.00 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Ad Behind the MarketsThis Weight Loss Company Can't Make Enough ProductA tiny pharmaceutical company is getting overwhelmed by a massive demand for its new weight loss marvel. They recently reported over 25,000 Americans are starting their drug each week - a 4X increase since December!Get the name of the company and their stock ticker here >>> Direxion Daily S&P Biotech Bear 3x Shares ExpensesTypeLABDHealth Care ETFsEquity ETFsNYSEARCA ETFsAll ETFsManagement Fee0.75%0.56%0.54%0.51%0.51%Other Expenses0.37%0.33%0.50%0.59%0.54%Total Expense1.12%0.70%0.70%0.74%0.71%Fee Waiver-0.02%-0.45%-0.55%-0.69%-0.60%Net Expense1.10%0.61%0.60%0.58%0.58% Direxion Daily S&P Biotech Bear 3x Shares (LABD) HoldingsTop 10 LABD HoldingsDREYFUS GOVT CASH MAN INSHolding Weight: 43.33%GOLDMAN FINL SQ TRSRY INST 506Holding Weight: 25.96%GOLDMAN SACHS FIN GOV 465 INSTITUTHolding Weight: 18.93%DREYFUS TRSRY SECURITIES CASH MGMTHolding Weight: 7.94%S&P BIOTECHNOLOGY SELECT INDUSTRY INDEX SWAPHolding Weight: -35.49%S&P BIOTECHNOLOGY SELECT INDUSTRY INDEX SWAPHolding Weight: -36.53%S&P BIOTECHNOLOGY SELECT INDUSTRY INDEX SWAPHolding Weight: -38.08%S&P BIOTECHNOLOGY SELECT INDUSTRY INDEX SWAPHolding Weight: -42.91%S&P BIOTECHNOLOGY SELECT INDUSTRY INDEX SWAPHolding Weight: -53.65%S&P BIOTECHNOLOGY SELECT INDUSTRY INDEX SWAPHolding Weight: -93.35%Full Holdings Details Similar ETFsALPS Medical Breakthroughs ETFNYSEARCA:SBIOSimplify Propel Opportunities ETFNYSEARCA:SURISimplify Health Care ETFNYSEARCA:PINKProShares Ultra Nasdaq BiotechnologyNASDAQ:BIBProShares Ultra Health CareNYSEARCA:RXLInstitutional OwnershipVirtu Financial LLCSold 271,141 shares on 5/20/2024Ownership: 3.548%AI Squared Management LtdBought 189,750 shares on 5/10/2024Ownership: 1.592%Headlands Technologies LLCBought 16,082 shares on 5/8/2024Ownership: 0.238%View All Institutional Transactions LABD ETF - Frequently Asked Questions How have LABD shares performed in 2024? Direxion Daily S&P Biotech Bear 3x Shares' stock was trading at $9.69 at the beginning of the year. Since then, LABD stock has decreased by 17.5% and is now trading at $7.99. View the best growth stocks for 2024 here. What does LABD invest in? Direxion Daily S&P Biotech Bear 3x Shares is a equity fund issued by Direxion. LABD focuses on health care investments and follows the S&P Biotechnology Select Industry Index. The fund's investments total to approximately $121.77 million assets under management. What is the management fee for Direxion Daily S&P Biotech Bear 3x Shares? Direxion Daily S&P Biotech Bear 3x Shares' management fee is 0.75% and has other expenses of 0.37%. However, LABD has a fee waiver of -0.02% to reimburse the expenses. The net expense ratio for LABD is 1.10%. When did Direxion Daily S&P Biotech Bear 3x Shares' stock split? Direxion Daily S&P Biotech Bear 3x Shares shares reverse split on Friday, August 28th 2020. The 1-20 reverse split was announced on Monday, July 27th 2020. The number of shares owned by shareholders was adjusted after the market closes on Thursday, August 27th 2020. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Direxion Daily S&P Biotech Bear 3x Shares own? Based on aggregate information from My MarketBeat watchlists, some companies that other Direxion Daily S&P Biotech Bear 3x Shares investors own include Direxion Daily S&P Biotech Bull 3x Shares (LABU), Micron Technology (MU), Intel (INTC), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Pfizer (PFE), Direxion Daily Semiconductors Bull 3x Shares (SOXL) and ProShares UltraPro Short QQQ (SQQQ). Who are Direxion Daily S&P Biotech Bear 3x Shares' major shareholders? Direxion Daily S&P Biotech Bear 3x Shares' stock is owned by a number of retail and institutional investors. Top institutional investors include Virtu Financial LLC (3.55%), AI Squared Management Ltd (1.59%) and Headlands Technologies LLC (0.24%). How do I buy shares of Direxion Daily S&P Biotech Bear 3x Shares? Shares of LABD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSEARCA:LABD) was last updated on 6/18/2024 by MarketBeat.com Staff From Our PartnersBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredBeta testers blew this thing upThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and fi...Prosper Trading Academy | SponsoredRadical change coming — do this NOW to protect yourselfI recently uncovered a way the government could use the next crisis as a pretext to gain more control … and ra...Weiss Ratings | SponsoredUnexpected twist to Trump’s trialUnexpected Twist to Trump's Trial Most folks sense there's more to the Trump trial than meets the eye. B...Stansberry Research | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredElon Musk: THIS will be bigger than TeslaIf you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you ...Paradigm Press | SponsoredMissed NVDA? Buy this AI stock NOWAfter Nvidia's record-breaking earnings surge, Wall Street is now selling the stock at the fastest pace in sev...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Direxion Daily S&P Biotech Bear 3x Shares Please log in to your account or sign up in order to add this asset to your watchlist. Share Direxion Daily S&P Biotech Bear 3x Shares With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.